TY - JOUR
T1 - Lymphatic space invasion is not an independent predictor of outcomes in early stage breast cancer treated by breast-conserving surgery and radiation
AU - Freedman, Gary M.
AU - Li, Tianyu
AU - Polli, Leonardo V.
AU - Anderson, Penny R.
AU - Bleicher, Richard J.
AU - Sigurdson, Elin
AU - Swaby, Ramona
AU - Dushkin, Holly
AU - Patchefsky, Arthur
AU - Goldstein, Lori
N1 - © 2012 Wiley Periodicals, Inc.
PY - 2012/9
Y1 - 2012/9
N2 - To study the prognostic importance of lymphovascular invasion (LVI) in early stage breast cancer after conservative surgery and radiation. From 2/80 to 8/07, 1,478 patients were treated with breast-conserving surgery and radiation with or without systemic therapy. Study eligibility included breast conservation, whole breast postoperative radiation, T1-T2 disease, and known LVI status. Endpoints were 5- and 10-year actuarial outcomes for local control and survival. LVI was present in 427 patients and absent in 1,051 patients. Median follow-up was 68 and 69 months, respectively. Patients with LVI had a younger median age, were more often pre- or perimenopausal, T2, physically palpable, invasive ductal, node positive, grade 3, and treated with chemotherapy compared with patients without LVI. The 5- and 10-year local-regional recurrence was 4.5% and 9.6% with LVI compared with 1.6% and 5.6% without LVI (p = 0.01). The 5- and 10-year overall survival was 83% and 68% for LVI and 91% and 80% for no LVI, respectively (p < 0.0001). Multivariate analysis showed that LVI was not an independent predictor of local-regional control (p = 0.0697) or survival (p = 0.1184). LVI in breast cancer is found in association with other worse prognostic factors for outcome, is associated with a modest increase in local-regional recurrence, but is not an independent predictor of local-regional recurrence or survival on multivariate analysis.
AB - To study the prognostic importance of lymphovascular invasion (LVI) in early stage breast cancer after conservative surgery and radiation. From 2/80 to 8/07, 1,478 patients were treated with breast-conserving surgery and radiation with or without systemic therapy. Study eligibility included breast conservation, whole breast postoperative radiation, T1-T2 disease, and known LVI status. Endpoints were 5- and 10-year actuarial outcomes for local control and survival. LVI was present in 427 patients and absent in 1,051 patients. Median follow-up was 68 and 69 months, respectively. Patients with LVI had a younger median age, were more often pre- or perimenopausal, T2, physically palpable, invasive ductal, node positive, grade 3, and treated with chemotherapy compared with patients without LVI. The 5- and 10-year local-regional recurrence was 4.5% and 9.6% with LVI compared with 1.6% and 5.6% without LVI (p = 0.01). The 5- and 10-year overall survival was 83% and 68% for LVI and 91% and 80% for no LVI, respectively (p < 0.0001). Multivariate analysis showed that LVI was not an independent predictor of local-regional control (p = 0.0697) or survival (p = 0.1184). LVI in breast cancer is found in association with other worse prognostic factors for outcome, is associated with a modest increase in local-regional recurrence, but is not an independent predictor of local-regional recurrence or survival on multivariate analysis.
KW - Antineoplastic Agents/therapeutic use
KW - Breast Neoplasms/drug therapy
KW - Carcinoma, Ductal, Breast/drug therapy
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Lymphatic Metastasis
KW - Mastectomy, Segmental
KW - Middle Aged
KW - Multivariate Analysis
KW - Prognosis
KW - Survival Rate
KW - Treatment Outcome
UR - http://www.scopus.com/inward/record.url?scp=84866112921&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000308589900004&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1111/j.1524-4741.2012.01271.x
DO - 10.1111/j.1524-4741.2012.01271.x
M3 - Article
C2 - 22776042
SN - 1075-122X
VL - 18
SP - 415
EP - 419
JO - Breast Journal
JF - Breast Journal
IS - 5
ER -